Literature DB >> 20947116

Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor.

M Calado1, P Matoso, Q Santos-Costa, M Espirito-Santo, J Machado, L Rosado, F Antunes, K Mansinho, M M Lopes, F Maltez, M O Santos-Ferreira, J M Azevedo-Pereira.   

Abstract

The human immunodeficiency virus replication cycle begins by sequential interactions between viral envelope glycoproteins with CD4 molecule and a member of the seven-transmembrane, G-protein-coupled, receptors' family (coreceptor). In this report we focused on the contribution of CCR8 as alternative coreceptor for HIV-1 and HIV-2 isolates. We found that this coreceptor was efficiently used not only by HIV-2 but particularly by HIV-1 isolates. We demonstrate that CXCR4 usage, either alone or together with CCR5 and/or CCR8, was more frequently observed in HIV-1 than in HIV-2 isolates. Directly related to this is the finding that the non-usage of CXCR4 is significantly more common in HIV-2 isolates; both features could be associated with the slower disease progression generally observed in HIV-2 infected patients. The ability of some viral isolates to use alternative coreceptors besides CCR5 and CXCR4 could further impact on the efficacy of entry inhibitor therapy and possibly also in HIV pathogenesis.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20947116     DOI: 10.1016/j.virol.2010.09.020

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

1.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitors.

Authors:  Maria Espirito-Santo; Quirina Santos-Costa; Marta Calado; Patrick Dorr; J Miguel Azevedo-Pereira
Journal:  AIDS Res Hum Retroviruses       Date:  2011-10-03       Impact factor: 2.205

3.  Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.

Authors:  Thushan I de Silva; Marlén Aasa-Chapman; Matthew Cotten; Stéphane Hué; James Robinson; Frederic Bibollet-Ruche; Ramu Sarge-Njie; Neil Berry; Assan Jaye; Peter Aaby; Hilton Whittle; Sarah Rowland-Jones; Robin Weiss
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

4.  CKR-L3, a deletion version CCR6-isoform shows coreceptor-activity for limited human and simian immunodeficiency viruses.

Authors:  Salequl Islam; Katsuaki Kanbe; Nobuaki Shimizu; Takahiro Ohtsuki; Atsushi Jinno-Oue; Atsushi Tanaka; Hiroo Hoshino
Journal:  BMC Infect Dis       Date:  2014-07-01       Impact factor: 3.090

5.  HIV-2 interaction with cell coreceptors: amino acids within the V1/V2 region of viral envelope are determinant for CCR8, CCR5 and CXCR4 usage.

Authors:  Quirina Santos-Costa; Maria Manuel Lopes; Marta Calado; José Miguel Azevedo-Pereira
Journal:  Retrovirology       Date:  2014-11-25       Impact factor: 4.602

6.  Membrane-associated GRP78 helps subgroup J avian leucosis virus enter cells.

Authors:  Lin Wang; Mei Mei; Aijian Qin; Jianqiang Ye; Kun Qian; Hongxia Shao
Journal:  Vet Res       Date:  2016-09-06       Impact factor: 3.683

7.  Repurposing Saquinavir for Host-Directed Therapy to Control Mycobacterium Tuberculosis Infection.

Authors:  David Pires; Sofia Valente; Marta Calado; Manoj Mandal; José Miguel Azevedo-Pereira; Elsa Anes
Journal:  Front Immunol       Date:  2021-03-26       Impact factor: 7.561

8.  Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates.

Authors:  Benoit Visseaux; Charlotte Charpentier; Gilles Collin; Mélanie Bertine; Gilles Peytavin; Florence Damond; Sophie Matheron; Eric Lefebvre; Françoise Brun-Vézinet; Diane Descamps
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

9.  Link between primate lentiviral coreceptor usage and Nef function.

Authors:  Jan Schmökel; Hui Li; Asma Shabir; Hangxing Yu; Matthias Geyer; Guido Silvestri; Donald L Sodora; Beatrice H Hahn; Frank Kirchhoff
Journal:  Cell Rep       Date:  2013-11-21       Impact factor: 9.423

10.  Glycosylated extracellular vesicles released by glioblastoma cells are decorated by CCL18 allowing for cellular uptake via chemokine receptor CCR8.

Authors:  Jordi Berenguer; Tonny Lagerweij; Xi Wen Zhao; Sophie Dusoswa; Petra van der Stoop; Bart Westerman; Mark C de Gooijer; Marloes Zoetemelk; Anoek Zomer; Matheus H W Crommentuijn; Laurine E Wedekind; Àlan López-López; Alberta Giovanazzi; Marina Bruch-Oms; Ida H van der Meulen-Muileman; Rogier M Reijmers; Toin H van Kuppevelt; Juan-Jesús García-Vallejo; Yvette van Kooyk; Bakhos A Tannous; Pieter Wesseling; Danijela Koppers-Lalic; W Peter Vandertop; David P Noske; Victor W van Beusechem; Jacco van Rheenen; D Michiel Pegtel; Olaf van Tellingen; Thomas Wurdinger
Journal:  J Extracell Vesicles       Date:  2018-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.